BK Virus (BKV) Infection - Pipeline Insight, 2024

This “BK Virus (BKV) Infection - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in BK Virus (BKV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

BK Virus (BKV) Infection: Understanding

BK Virus (BKV) Infection: Overview

BK virus (BKV) is a common opportunistic pathogen in kidney transplant recipients and one of the most challenging causes of allograft dysfunction and loss. This virus was named after a Sudanese kidney transplant recipient with ureteric stenosis who was the first patient to have BKV isolated from the urine. It is a double-stranded circular DNA virus, member of the Betapolyomavirus genus in the Polyomaviridae family.

Following primary infection, BKV spreads and infects renal tubular epithelial cells and epithelial cells of the urogenital tract, where it remains latent. Several factors including allograft, viral, and host factors influence reactivation of BKV. Upon reactivation, the infected renal tubular epithelial cells develop an increase in nuclear size and generate intranuclear basophilic inclusions. These cells detach from the basement membrane and appear in urine as decoy cells. A wide array of genomic changes follows within 48 hours of viral proliferation in the human tubular epithelial cells that regulate fundamental biological processes such as cell cycle, apoptosis, DNA damage, and release of immune mediators, all of which contribute to the lytic phase of viral reactivation and its persistence in the renal allograft.

Cellular immunity and in particular memory cell function is considered to be the cornerstone for controlling the latent viral state and suppressing viremia and BKV-associated nephropathy. Healthy seropositive individuals have a strong BKV-specific T-cell response, whereas seronegative healthy individuals do not.

BKV reactivation results in tubulointerstitial nephritis and, infrequently, ureteric stenosis in kidney transplant recipients and hemorrhagic cystitis in hematopoietic stem cell transplant recipients. However, case reports exist of BKV causing pneumonitis, retinitis, vasculopathy, meningoencephalitis, and Guillain-Barré syndrome, among other manifestations.

"BK Virus (BKV) Infection- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the BK Virus (BKV) Infection pipeline landscape is provided which includes the disease overview and BK Virus (BKV) Infection treatment guidelines. The assessment part of the report embraces, in depth BK Virus (BKV) Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, BK Virus (BKV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence BK Virus (BKV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve BK Virus (BKV) Infection.

BK Virus (BKV) Infection Emerging Drugs Chapters

This segment of the BK Virus (BKV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

BK Virus (BKV) Infection Emerging Drugs

• Brincidofovir: SymBio Pharmaceuticals

Brincidofovir is an orally available broad-spectrum antiviral agent with activity against various viruses, including BK virus. Studies have indicated that Brincidofovir inhibits BK polyomavirus replication in primary human urothelial cells, suggesting its potential effectiveness in combating BK virus infections. Additionally, Brincidofovir has been used in cases of BK virus-associated nephropathy after allogeneic hematopoietic stem cell transplantation, showing promise in managing these challenging conditions. It is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of BK Virus (BKV) Infection.

BK Virus (BKV) Infection: Therapeutic Assessment

This segment of the report provides insights about the different BK Virus (BKV) Infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in BK Virus (BKV) Infection

• There are approx. 4+ key companies which are developing the therapies for BK Virus (BKV) Infection. The companies which have their BK Virus (BKV) Infection drug candidates in the most advanced stage, i.e. Phase II include, SymBio Pharmaceuticals.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

BK Virus (BKV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

BK Virus (BKV) Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses BK Virus (BKV) Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BK Virus (BKV) Infection drugs.

BK Virus (BKV) Infection Report Insights

• BK Virus (BKV) Infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

BK Virus (BKV) Infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing BK Virus (BKV) Infection drugs?
• How many BK Virus (BKV) Infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of BK Virus (BKV) Infection?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the BK Virus (BKV) Infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for BK Virus (BKV) Infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• SymBio Pharmaceuticals
• AlloVir
• Memo Therapeutics

Key Products

• Brincidofovir
• Posoleucel
• AntiBKV

This product will be delivered within 2 business days.